GW Pharmaceuticals plc (NASDAQ:GWPH, AIM:GWP, AIM:GW) reported its financial results for the first quarter ended 31 December 2015.

GW Pharmaceuticals plc (NASDAQ:GWPH, AIM:GWP, AIM:GW) reported its financial results for the first quarter ended 31 December 2015.
According to the company:

RECENT OPERATIONAL HIGHLIGHTS
Epidiolex^® (CBD) childhood epilepsy program:
Company sponsored Phase 3 development programs in Dravet syndrome and Lennox-Gastaut syndrome (LGS)
First Phase 3 Dravet syndrome trial fully enrolled above original target sample size (120 randomized), data expected March 2016
Second Phase 3 Dravet syndrome trial ongoing, data expected H2 2016
Both LGS Phase 3 trials fully enrolled above original target sample sizes (171 for 2-arm, 225 for 3-arm randomized), data expected Q2 2016
97% transition rate of eligible patients from Phase 3 trials to long term open label extension
NDA submission with FDA expected Q4 2016
Phase 3 Tuberous Sclerosis Complex trial due to commence Q1 2016
Additional clinical development for Epidiolex expected to commence in H2 2016
Expanded access program
Recent data update at the American Epilepsy Society December 2015 Annual Meeting showing promising safety and effectiveness consistent with prior updates
Over 375 children and young adults on treatment at 22 U.S. clinical sites
Over 900 children and young adults authorized for treatment by FDA under Expanded Access Treatment INDs and 6 U.S. State programs
Advanced clinical programs in multiple cannabinoid pipeline product candidates:
THCV Phase 2 study in type-2 diabetes data expected Q2 2016
THC:CBD Phase 1b/2a study for the treatment of Recurrent Glioblastoma Multiforme (GBM) fully enrolled with data expected in mid-2016
Orphan Drug Designation granted from FDA and EMA
Sativex^® Phase 2 study in spasticity due to cerebral palsy ongoing with data expected H2 2016
CBDV Phase 2 partial-onset epilepsy study in adults ongoing. Part A complete and Part B underway with data expected around the end of 2016
Neonatal Hypoxic-Ischemic Encephalopathy (NHIE) intravenous CBD Phase 1 clinical program expected to commence in H2 2016
Orphan Drug and Fast Track Designations granted from FDA and EMA
Clinical trials within the field of autism spectrum disorders expected to commence in H2 2016
Pre-clinical progress addressing a number of areas of unmet need including autism spectrum disorders, Duchenne muscular dystrophy, glioma, ovarian and pancreatic cancers